Other Clinical Trial - MULTivessel Immediate Versus STAged

Status Completed

Clinical Trial Summary

The primary objective of the trial is to compare, in patients presenting with ST segment elevation myocardial infarction (STEMI) and multi-vessel disease (MVD), the safety and efficacy of immediate complete revascularization of all significant coronary lesions versus culprit vessel only revascularization and staged percutaneous coronary intervention (PCI) of all significant coronary lesions (within 19 to 45 days), in a non-inferiority trial using a third generation, biodegradable-polymer, everolimus-eluting stent.

Clinical Trial Description

An investigator-initiated, randomized, multicenter, two-arm, open-label study of consecutive patients presenting with STEMI and MVD in stable hemodynamic conditions, undergoing after successful PCI of the culprit lesion either (1:1 randomization) immediate revascularization of all additional target lesions during the index procedure or staged PCI of all additional target lesions (within 19 to 45 days) using the Boston Scientific Synergy™ stent. The goal of this trial is to compare two treatment strategies that are currently performed in clinical practice: immediate complete revascularization versus staged complete revascularization in patients with STEMI and MVD. Patients randomized to immediate complete revascularization will have treated during the index procedure, after revascularization of the culprit lesion, all significant non-culprit coronary lesions. Patients randomized to staged complete revascularization will have treated during the index procedure only the culprit lesion, and they will be hospitalized after 19-45 days for complete revascularization of all significant non-culprit coronary lesions. For both groups, lesion are considered significant when causing a ≥70% diameter stenosis by visual estimation in at least two projections on the coronary angiogram. ;

Study Design

Related Conditions & MeSH terms

Coronary Artery Disease
Coronary Disease
Infarction
Multivessel Coronary Disease
Myocardial Infarction
ST Elevation Myocardial Infarction
ST-elevation Myocardial Infarction

Clinical Trial Details

NCT number	NCT03135275
Study type	Interventional
Source	University of Zurich
Contact
Status	Completed
Phase	N/A
Start date	October 2016
Completion date	May 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01864343` - Target Temperature Management In Myocardial Infarction - A Pilot Study	N/A
Completed	`NCT00962416` - Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction (STEMI)	Phase 4
Active, not recruiting	`NCT00927615` - Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO)	N/A
Recruiting	`NCT02592694` - Intracoronary Cocktail Injection Combined With Thrombus Aspiration in STEMI Patients Treated With Primary Angioplasty	Phase 4
Withdrawn	`NCT01991366` - Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?
Completed	`NCT02158468` - Effect of Conditioning on Myocardial Damage in STEMI	N/A
Completed	`NCT01197729` - OPTAMI (Optimized Therapy of Acute Myocardial Infarction) - Registry	N/A
Completed	`NCT01882179` - Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size	Phase 3
Terminated	`NCT00719914` - A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks	Phase 2
Completed	`NCT00952224` - Myocardial Salvage Assessed by Cardiovascular Magnetic Resonance - Impact on Outcome	N/A
Completed	`NCT00378391` - European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry	N/A
Withdrawn	`NCT04303377` - Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction	Phase 2
Completed	`NCT03523624` - Factor XIII and Other Biomarkers in ST Segment Elevation Myocardial Infarction
Completed	`NCT01531114` - PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus	Phase 3
Active, not recruiting	`NCT01960933` - Primary PCI in Patients With ST-elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization	N/A
Completed	`NCT00502528` - Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction	Phase 2
Recruiting	`NCT02062554` - Brasilia Heart Study
Recruiting	`NCT04150016` - In-stent Repair and Vessel Reaction of STEMI Patients With OCT	N/A
Recruiting	`NCT03074214` - Prognostic Value of Copeptin for Infarct Size and Prognosis in Patients With ST-elevation Myocardial Infarction	N/A
Not yet recruiting	`NCT05231226` - Timing of Complete Revascularization in Patients With ST-segment Elevation Myocardial Infarction And Multivessel Disease	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction -The MULTISTARS AMI Trial — MULTISTARS AMI

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms